<DOC>
	<DOCNO>NCT01460901</DOCNO>
	<brief_summary>This single-center , investigator-initiated , single-arm , pilot study post-allogeneic transplant , adoptive immunotherapy treatment patient relapsed/refractory neuroblastoma express mesenchymal tumor marker GD2 . Three patient treat . The study focus safety efficacy allogeneic , donor derive viral specific cytotoxic T-lymphocytes , retrovirally transduce express chimeric antigen receptor specific disialoganglioside , GD2 , express neuroblastoma .</brief_summary>
	<brief_title>Study Donor Derived , Multi-virus-specific , Cytotoxic T-Lymphocytes Relapsed/Refractory Neuroblastoma</brief_title>
	<detailed_description>Neuroblastoma ( NB ) common extracranial tumor childhood prognosis patient relapse refractory disease &lt; 10 % standard therapy patient . Research toward immunotherapeutic agent intensify monoclonal antibody target GD2 , incorporate upfront NB therapy , prolongs survival . Allogeneic Hematopoietic stem cell transplantation ( HSCT ) utilize patient NB evidence graft versus tumor ( GVT ) effect transplant relate mortality ( TRM ) nullify survival benefit . In effort harness GVT effect allogeneic transplant lower TRM , harvest viral specific cytotoxic T-cells donor infuse early post-HSCT HSCT recipient shorten recovery immunity toward significant viral infection . The investigator also retrovirally transduce viral specific CTL chimeric antigen receptor ( CAR ) gene complex tV-CTL expand , via native T-cell receptor response viral infection post-HSCT carry capability kill tumor cell transduce receptor , extracellular component CAR , specificity GD2 express surface NB . In essence , investigator intend take specificity monoclonal antibody GD2 , already utilized therapy NB , combine specificity cytotoxicity T-cells target NB . The investigator hypothesize infusion safe viral specificity tV-CTL provide long term immunity viral infection investigator see anti-tumor effect .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Allogeneic transduce tVCTLs &gt; 15 % expression 14g2a.zeta chimeric antigen receptor Patient responsible person must able understand sign permission/assent consent form infusion Age 18 month 17 year time relapse/progression Life expectancy &gt; 8weeks Karnofsky score 60 % great 10 yr old old . Lansky score 60 % great 10 yr old Patient must HIV negative ANC &gt; 500 Pulse ox &gt; 90 % room air AST/ALT/direct bili &lt; 5x upper limit normal Recovered toxic effect prior chemotherapy Absence human/antimouse antibody ( HAMA ) ( patient receive prior therapy murine antibody ) &gt; 50 % donor engraftment Patient pregnant lactating refuse birth control method HIV positive Uncontrolled intercurrent infection Renal failure ( creatinine clearance &lt; 40ml/min/1.73m2 ) Active hepatitis cirrhosis bilirubin , AST , ALT &gt; 5xnormal Rapidly progressive disease Currently receive investigational drug Tumor potentially cause airway obstruction Cardiomegaly bilateral pulmonary infiltrates CXR Receiving &gt; 0.25mg/kg/day methylprednisolone equivalent systemic steroid . Topical steroid therapy acceptable Receiving one lymphocyte inhibiting agent ( ex . Tacrolimus/CSA MMF similar agent Patients relapse progress age 18 month Stage I/II disease , and/or , opinion oncologist , may benefit conventional therapy Donor lymphocyte infusion last 28 day Evidence GvHD great equal grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>